Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.)
![]() |
|||
Mailing Address: | 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 |
Head Office Address: | 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 |
Contact Name: | Daniel Yelin | Principal Regulator: | Quebec |
Business e-mail address: | Daniel.yelin@bauschhealth.com | Short Form Prospectus Issuer: | Yes |
Telephone Number: | 514 744-6792 | Reporting Jurisdictions: | British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland |
Fax Number: | Stock Exchange: | TSX, NYSE | |
Date of Formation: | Mar 29 1994 | Stock Symbol: | BHC |
Jurisdiction Where Formed: | British Columbia | Auditor: | PricewaterhouseCoopers LLP |
Industry Classification: | consumer products - biotechnology/pharmaceuticals | General Partner: | |
CUSIP Number: | 91911K | Transfer Agent: | AST Trust Company (Canada) |
Financial Year-End: | Dec 31 | Size of Issuer (Assets): | Over $1,000,000,000 |
![]() |